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Purpose: Studies have shown a strong association of human leukocyte antigens-B51 (HLA-B51) with Behçet’s disease
(BD). However, little is known about the association of non-HLA genes with BD. The polymorphisms of the Fc receptor-
like 3 gene (FCRL3), −169C/T, −110A/G, +358C/G, and +1381A/G, have been reported to be associated with several
autoimmune diseases. This study was designed to determine whether the polymorphisms of FCRL3 were associated with
susceptibility to BD in a Chinese population mainly with ocular involvement.
Methods: A case-control study was performed in 245 Chinese BD patients and 289 controls. Four single nucleotide
polymorphisms (SNPs; −169C/T, −110A/G, +358C/G, and +1381A/G) in FCRL3 were detected using polymerase chain
reaction restriction fragment length polymorphisms (PCR-RFLP). HLA-B51 genotyping was performed by the PCR
sequence specific primers method as described previously.
Results: The results showed a significantly higher frequency of the G allele at the −110 site in BD patients compared with
that in controls (corrected p=0.044, 75.3% versus 67.5%, χ2=7.72). Haplotype CGCG frequency was significantly higher
in patients than in controls (corrected p=0.0096) whereas haplotype TACG frequency was significantly lower in patients
compared with controls (corrected p=0.032). There was no relationship between clinical signs and FCRL3 polymorphisms.
No significant difference was observed between patients and controls after HLA-B51 stratification concerning the four
SNPs.
Conclusions: Our study suggests that the −110 G allele and the haplotype CGCG of FCRL3 are positively associated with
BD in a Chinese population and that the haplotype ATCG might be a protective haplotype for BD.
Behçet’s  disease  (BD)  is  an  idiopathic,  multisystem,
recurrent chronic inflammatory disease in China. The major
clinical  manifestations  include  recurrent  oral  and  genital
ulceration, uveitis, and erythema nodosum. Panuveitis was the
most  common  type  of  uveitis  in  BD  patients  in  China,
although solo anterior uveitis is observed in certain patients
[1].  BD  exists  worldwide  and  has  significant  regional
differences. It is quite common along the ancient ‘Silk Road’
countries extending from China to the Mediterranean area
[2]. Although the precise etiology of BD remains unknown,
extensive  studies  suggest  that  autoimmunity  and  genetic
factors are involved in its pathogenesis. It has been shown that
polymorphisms of several genes such as human leukocyte
antigens-B51 (HLA-B51), intercellular adhesion molecule-1
(ICAM-1) [3], and tumor necrosis factor–α (TNF–α) [4] are
associated with susceptibility to BD. Among these genes,
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HLA-B51 is the most strongly associated gene with BD in
different ethnic populations [5-8], particularly those from the
Middle  East  to  the  Far  East  [9],  coinciding  with  the
distribution of BD.
Fc receptor-like genes (FCRLs), also known as FCRHs
(Fc  receptor  homology)  or  IRTAs  (immunoglobulin
superfamily receptor translocation associated genes) [10], and
SPAPs (SH2 domain containing phosphatase anchor proteins)
cluster on human chromosome 1q21–23 adjacent to the Fc
receptor genes [11]. FCRLs have a high structural homology
with the classical Fcγ receptor genes (FcγR) and contain six
Ig superfamily members that are known as FCRL1–FCRL6
according  to  their  chromosomal  order  [12].  Recently,  a
classical study by Kochi et al. [13] in Japan found that four
single nucleotide polymorphisms (SNPs) of FCRL3 (−169C/
T, −110A/G, +358C/G, and +1381A/G) were associated with
rheumatoid arthritis (RA) and that SNP rs7528684C/T was
associated  with  autoimmune  thyroid  disease  (AITD)  and
systemic lupus erythematosus (SLE). As various autoimmune
disorders may share common pathogenic pathways, genes that
have been found to be involved in one autoimmune disease
Molecular Vision 2008; 14:2136-2142 <http://www.molvis.org/molvis/v14/a250>
Received 10 October 2008 | Accepted 19 November 2008 | Published 28 November 2008
© 2008 Molecular Vision
2136may also be considered as a candidate associated with other
autoimmune diseases. Until now, a FCRL3 polymorphism has
yet  to  be  investigated  in  BD.  Therefore,  this  study  was
designed to investigate the association of the aforementioned
four SNPs of FCRL3 (−169C/T, −110A/G, +358C/G, and
+1381A/G) with susceptibility to BD in a Chinese population,
mainly with ocular involvement. The result showed a positive
association of the −110G allele and the haplotype CGCG and
a negative association of the haplotype TACG with BD.
METHODS
Study participants: Patients and controls were recruited from
the Zhongshan Ophthalmic Center of Sun Yat-sen University
(Guangzhou, P.R. China) and the First Affiliated Hospital of
Chongqing Medical University (Chongqing, P.R. China). The
test  subjects  consisted  of  245  Chinese  BD  patients  (aged
28.6±6.0 years) and 289 healthy controls (aged 34.2±10.0
years).  All  control  subjects  were  matched  ethnically  and
geographically with the patients.
The diagnosis of Behçet’s disease followed the criteria of
the International Study Group for Behçet’s disease [14]. The
clinical characteristics of the patients are presented in Table
1. All subjects gave their written informed consent for this
study,  and  the  study  protocol  was  approved  by  the  local
institutional ethics committee.
Single nucleotide polymorphisms and genotyping: DNA was
prepared by proteinase K digestion and salt extraction from
peripheral blood of patients and controls and stored at −70 °C
until  use.  The  four  SNPs  in  FCRL3,  namely  −169C/T
(rs7528684 or fcrl3_3), −110G/A (rs11264799 or fcrl3_4),
+358 C/G (rs945635 or fcrl3_5), and +1381A/G (rs3761959
or fcrl3_6), were genotyped by polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP) .
Genotyping  of  the  −110A/G  SNP  was  performed
according to the method as described previously [15]. The
primers  of  the  three  remaining  sites  were  designed  using
Primer Premier 5.0 software (Premier Biosoft International,
Palo Alto, CA). The details of the primers and enzymes used
for PCR-RFLP genotyping are presented in Table 2.
TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH BD.
Clinical features
Patients (n=245)
N %
Male 204 83.3
Female 41 16.7
Uveitis 235 95.9
Hypopyon 53 21.6
Oral ulcer 226 92.2
Skin lesions 120 49
Genital ulcer 95 38.8
Positive pathergy 81 33.1
Arthritis 60 24.5
N=number of patients.
PCR was performed in 15 μl volumes containing 7.5 μl
Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co.
Ltd, Dalian, China), 0.5 μl primers (10 μmol/l), and 0.1 μg of
genomic DNA. The PCR products were then digested by the
proper restriction enzymes and separated by electrophoresis
on 2~3% agarose gels and stained with GoldView™ (SBS
Genetech,  Beijing,  China).  The  images  were  recorded
digitally. HLA-B51 genotyping was performed by the PCR-
sequence specific primers (PCR-SSP) method as described
previously [16].
Statistical analysis: Statistical analysis was performed with
the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL).
Hardy–Weinberg equilibrium (HWE) was tested by the χ2 test.
We evaluated the frequency of genotypes and alleles in this
study using the χ2 test or Fisher’s exact test. The haplotype
frequency and linkage disequilibrium (LD) of the SNPs were
estimated with the Haploview 3.2 program [17]. A haplotype
frequency less than 0.03 was not studied further. All the data
were corrected by Bonferroni correction.
RESULTS
Four SNPs in FCRL3 were determined in 245 BD patients and
289 healthy controls. The results showed that all the cases and
controls were in HWE. We analyzed LD with these four SNPs
and haplotype analysis with Haploview software, and the four
SNPs of FCLR3 are not in high LD (D’=46–87; r2=0.10–0.74;
Figure 1). The frequency of the G allele at the −110 site was
Figure 1. Location and pair-wise linkage disequilibrium values of
four FCRL3 SNPs in a Chinese population. These four SNPs span 1
kb of the FCRL3 region. Values of the pair-wise D’ (multiply by 100)
are shown in one block.
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2137significantly  higher  in  patients  (75.3%)  than  in  controls
(67.5%; corrected p=0.044, χ2=7.72; Table 3). The −110 GG
genotype was also found to be increased in patients (p=0.007),
but  this  significance  was  lost  after  Bonferroni  correction
(corrected p=0.084). The frequency of the −169C:−110G:
+358C:+1381G haplotype was significantly higher in patients
compared with controls (13.3% versus 7.0%, respectively;
p=6.0×10−4,  corrected  p=0.0096,  χ2=11.70;  Table  4).  The
frequency of haplotype −169T:−110A:+358C:+1381G was
significantly lower in patients than that in controls (3.0%
versus  7.0%,  respectively;  p=0.002,  corrected  p=0.032,
χ2=9.27; Table 4). No significant difference in the remaining
three SNPs tested was observed between BD patients and
controls in the distribution of other alleles and genotypes.
TABLE 2. DETAILS OF THE PRIMERS AND ENZYMES USED FOR PCR-RFLP GENOTYPING.
SNPs
dbSNP
   ID Forward primer Reverse primer
Tm                Restriction
enzyme
−169C/T(fcrl3_3) rs7528684 GGAAAATAATACA
AATGTACAGATTA
  GGCTTTAAAA                           56.9
AACGGTGGTAC
BsmFI
−110A/G(fcrl3_4) rs11264799 CTCAATCCCGGT
AGTGATACA
CTCATAACAAC                          56.9
  TTATGTGAGA
Ple I
+358C/G(fcrl3_5) rs945635 TTATAGCCCATCTA
CTCACTCAGGATCA
CCGGGATTGAGA
TACAAACAGCATTT
60.3 HaeIII
+1381A/G(fcrl3_6) rs3761959 TCCGACTTTTTCA
GTCTCTAGGTTTT
TGATAGCAGCACTA
GCTTGGACATTCA
60.3 MspI
Tm=melting temperature
TABLE 3. FREQUENCY OF ALLELES AND GENOTYPES OF FOUR FCRL3 SNPS IN BD PATIENTS AND CONTROLS.
SNPs Genotype/ allele BD (%) Controls (%) χ2 p Corrected p OR (95% CI)
−169 C→T
 
 
 
  CC 69 (28.3) 86 (29.8) 1.95 0.38 NS
CT 121 (49.6) 127 (43.9)
TT 54 (22.1) 76 (26.3)
C 259 (53.3) 299 (51.7) 0.26 0.61                    NS                      1.1 (0.8–1.3)
T 227 (46.7) 279 (48.3) 0.9 (0.7–1.2)
−110 A→G
 
 
 
  AA 17 (7.1) 46 (16.0) 10.03 0.007 NS
AG 85 (35.3) 95 (33.0)
GG 139 (57.7) 147 (51.0)
A 119 (24.7) 187 (32.5) 7.72         0.0055                0.044                     0.7 (0.5–0.9)
G 363 (75.3) 389 (67.5) 1.5 (1.1–1.9)
358 C→G
 
 
 
  CC 81 (33.2) 97 (33.6) 1.12 0.57 NS
CG 122 (50.0) 134 (46.4)
GG 41 (16.8) 58 (20.1)
C 283 (58.0) 328 (56.7) 0.17 0.68                    NS                       1.1(0.8–1.4)
G 205 (42.0) 250 (43.3) 0.9(0.7–1.2)
1381 A→G
 
 
 
 
AA 40 (16.4) 54 (18.8) 0.5 0.78 NS
AG 122 (50.0) 140 (48.6)
GG 82 (33.6) 94 (32.6)
A 203 (58.4) 248 (56.9) 0.23 0.63                   NS                       0.9 (0.7–1.2)
G 285 (41.6) 328 (43.1) 1.1 (0.8–1.4)
BD= Behçet’s disease; OR=odds ratio; 95% CI=95% confidence interval; NS=not significant.
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(°C)Since the BD patients showed different clinical features,
we further analyzed the relationship between the SNPs and
various clinical parameters such as uveitis, hypopyon, oral or
genital  ulcers,  multiform  skin  lesions,  and  arthritis.  No
significant  difference  was  noted  between  any  of  the
mentioned clinical characteristics and the investigated SNPs.
Of the 245 patients, 204 (83.3%) were men and 41 (16.7%)
were women. No significant difference was found in the four
SNPs between male and female patients.
As HLA-B51 has been shown to be strongly associated
with BD, we also investigated its frequency in patients and
controls. The result showed that 99 (40.4%) patients were
HLA-B51 positive as compared to 28 (9.7%) of the controls,
a  significant  difference.  HLA-B51  stratification  analysis
showed a significant difference for the −110 A/G allele, the
AA genotype, and the haplotype CGCG and TACG. The
difference, however, lost its significance when the Bonferroni
correction was applied (Table 5).
DISCUSSION
In this study, we analyzed the association of four FCRL3 SNPs
with BD in a Chinese population. The results showed that the
−110G allele was significantly increased in the BD patients.
The frequency of the haplotype CGCG was also found to be
significantly  increased  in  these  patients  whereas  a
significantly decreased frequency of haplotype TACG was
noted. These results suggest that polymorphisms of FCRL3
are associated with the susceptibility to BD in a Chinese
population.
BD is one of the most common uveitis entities in China
[1]. Its distribution along the old ‘Silk Road’ and the clustering
of the disease in families suggest that genetic factors may play
a role in the pathogenesis of this disease. HLA-B51 has been
shown to be strongly associated with BD in different ethnic
populations. Little is known about the association of non-HLA
genes with BD, although polymorphisms of several genes
have been investigated in this disease [3,4]. In this study, we
focused on the association of four FCRL3 SNPs with BD
mainly  because  of  the  role  this  gene  may  play  in  the
pathogenesis of autoimmunity and its association with other
autoimmune diseases. FCRL have been shown to have a high
structural  homology  with  the  classical  FcγR,  which  are
expressed mainly on the surface of a variety of immune cells.
Moreover, previous studies showed that polymorphisms of
FCγR were associated with a variety of autoimmune diseases
[18,19]. FCRL has been found to be expressed predominantly
on B cells and has also been detected at low levels in CD4+
and  CD8+  T  cells  [13].  FCRL3  may  play  a  role  in  the
differentiation of B cells into autoreactive cells and has been
presumed to function through modulating signal transduction
via  activation/inactivation  of  signaling  tyrosine  protein
kinases [20]. Furthermore, the −169C/T SNP of FCRL3 has
been shown to influence the level of FCRL3 expression on B
cells through altering the binding affinity of the nuclear factor-
kappa-B  (NF-κB)  [13],  an  important  immunoregulatory
factor, according to recent studies in both murine models and
humans with diverse forms of autoimmunity [21]. It is not
clear whether the −110 SNP has any functional role. The
association of this SNP with BD as disclosed in our study
appears to suggest a possible involvement of FCRL3 in the
development of BD.
Our study showed a significantly higher frequency of the
G allele at the −110 site in BD patients, which is consistent
with that observed in patients with autoimmune Addison’s
disease  (AAD)  in  a  UK  population  [15].  This  identical
polymorphism  between  BD  and  AAD  seemed  to  show  a
susceptibility that both have in common. Interestingly, two
studies  by  Japanese  investigators  showed  a  decreased
frequency  of  the  G  allele  in  the  −110  site  in  RA  and
autoimmune  pancreatitis  [13,22].  Furthermore,  a  study
reported by Simmonds et al. [23] showed that three of the four
SNPs studied here (the −110 SNP was the exception) were
associated with Graves’ disease.
With regard to the haplotype analysis, we found two
haplotypes, CGCG and TACG, that were associated with BD.
The former was found to be significantly higher in BD patients
while the latter was lower in BD patients. The findings suggest
that the FCRL3 −110G allele may be linked with susceptibility
to BD, and those people with the haplotype CGCG are more
prone  to  BD  than  those  without  this  haplotype.  On  the
contrary,  the  haplotype  ATCG  might  be  a  protective
haplotype to BD. Our results were different from those found
in AAD [15] and SLE [24]. In the study of AAD, seven alleles
and haplotypes were investigated, the haplotype TGGGAAA
TABLE 4. HAPLOTYPE FREQUENCIES IN BD PATIENTS AND CONTROLS.
   BD 
Haplotypes          n=245 (%)
Controls
n=289 (%) χ2
Fisher’s               Corrected
      p                            p OR
TGCG 180.4 (37.0) 210.5 (36.4) 0.033 0.86 NS 1.1 (0.9–1.5)
CAGA 89.0 (18.2) 116.0 (20.1) 0.57 0.45 NS 1.0 (0.8–1.4)
CGGA 84.2 (17.2) 106.9 (18.5) 0.28 0.6 NS 0.8 (0.6–1.1)
CGCG 64.9 (13.3) 40.6 (7.0) 11.7 0.0006 0.0096 2.4 (1.6–3.7)
TACG 14.5 (3.0) 41.3 (7.0) 9.27 0.002 0.032 0.3 (0.1–0.6)
BD=Behçet’s disease; OR=odds ratio; NS=not significant.
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2139was found to be significantly increased among AAD patients
compared to the controls. In the study of SLE, the frequency
of haplotype CGA was found to be significantly higher among
SLE patients compared to the controls.
As BD shows a variety of manifestations clinically and
the  aforementioned  result  revealed  an  association  of  the
polymorphisms of FCRL3 with this disease, it is reasonable
to  test  whether  certain  clinical  features  are  linked  to  this
polymorphism. Unexpectedly, none of the clinical features
including  uveitis,  hypopyon,  oral  ulcer  or  genital  ulcer,
multiform  skin  lesions,  and  arthritis  were  found  to  be
associated with the identified susceptible allele at the −110
site. Similarly, there was no association between any of the
investigated clinical features and the haplotypes. These results
are  generally  consistent  with  those  in  a  previous  study
performed  in  our  laboratory  recently  searching  for  an
association between SUMO4 polymorphisms and BD. This
study found no association between haplotype AGAT, which
was already found to be significantly lower in BD patients,
and any of the clinical characteristics in BD patients [25].
However, it is worthwhile to point out that there was a bias in
the recruited BD patients in our current study. All the patients
enrolled in this study came from ophthalmic centers, and the
results  merely  revealed  the  association  of  the  FCRL3
polymorphisms  with  BD  patients,  mainly  with  ocular
involvement. The association of FCRL3 polymorphisms with
BD in the whole population with this disease should be studied
on the patients from dermatology and rheumatology centers.
Previous  studies  have  showed  that  the  association  of
FCRL3  with  diseases  could  be  more  striking  after
stratification  with  some  parameters  [26,27].  Genetic
susceptibility to BD is well documented for HLA-B51. We
therefore analyzed the association of the −110 SNP and the
remaining three SNPs with BD based on the HLA-B51 antigen
stratification. Unfortunately, we did not find any association
of these SNPs and haplotypes with BD after stratification for
TABLE 5. FREQUENCY OF ALLELES AND GENOTYPES AT FOUR FCRL3 SNPS IN HLA-B51 NEGATIVE BD PATIENTS AND IN HLA-B51 NEGATIVE CONTROLS.
SNPs Genotype/allele BD n=146 (%) Controls
n=261 (%) χ2
                Corrected                        OR
p                      p                          (95% CI)
−169 C→T
 
 
 
  CC 45 (30.8) 77 (29.5) 0.22 0.9 NS
CT 67 (45.9) 118 (45.2)
TT 34 (23.3) 66 (25.3)
C 159 (54.1) 272 (52.1)             0.29            0.59                  NS                       1.1 (0.8–1.4)
T 135 (45.9) 250 (47.9) 0.9 (0.7–1.2)
−110 A→G
 
 
    AA 10 (6.9)                  43 (16.5)             7.73             0.02                  NS
AG 56 (38.6) 86 (33.1)
GG 79 (54.5) 131 (50.4)
A 76 (26.0) 172 (33.1)            4.38              0.04                 NS                        0.7 (0.5–1.0)
G 216 (74.0) 348 (66.9) 1.4 (1.0–1.9)
+358 C→G
 
 
 
  CC 47 (32.2)                85 (32.6)             0.24             0.89 NS
CG 73 (50.0) 125 (47.9)
GG 26 (17.8) 51 (19.5)
C 168 (57.1) 295 (56.5)           0.03             0.86                  NS                        1.0 (0.8–1.4)
G 126 (42.9) 227 (43.5) 1.0 (0.7–1.3)
+1381 A→G
 
 
 
  AA 26 (17.8)                49 (18.8)              0.5              0.78 NS
AG 72 (49.3) 127 (48.8)
GG 48 (32.9) 84 (32.3)
A 125 (42.5) 225 (43.3)           0.043            0.84                  NS                       1.0 (0.7–1.3)
G 169 (57.5) 295 (56.7) 1.0 (0.8–1.4)
BD= Behçet’s disease; OR=odds ratio; 95% CI=95% confidence interval; NS= not significant.
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2140HLA-B51. This could be due to the insufficient sample size.
Our sample size for the −110 SNP (28 HLA-B51 positive
normal controls and 99 HLA-B51 positive BD patients) can
only reach a 26% power value to detect a 2.0 odds ratio (OR)
value at the 5% significance level. As there is a substantial
difference in clinical manifestations between male and female
BD patients, a stratification analysis according to sex was also
performed  in  our  study.  Similarly,  there  was  also  no
association following sex stratification in these patients. The
small size of the sample for the female BD patients may be
insufficient  for  this  analysis.  Therefore,  a  larger  patient
population is needed to clarify the association of FCRL3 with
Behcet’s disease in different HLA and sex status.
In conclusion, our study revealed that the −110G allele
and haplotype CGCG are positively associated and haplotype
TACG is negatively associated with the susceptibility to BD.
These results may provide clues for the development of an
adequate  and  effective  therapy  [28].  A  pharmacogenomic
relationship  has  been  studied  in  open-angle  glaucoma
between  β1-adrenergic  receptor  with  betaxolol,  between
prostaglandin F2α receptor and the latanoprost, and between
glucocorticoid receptor and intraocular pressure [29]. It is
important to test whether the polymorphisms revealed by our
study are associated with the sensitivity of certain medicines
in the treatment of BD. As a multi-systemic autoimmune
disease, BD may share mechanisms in common with other
autoimmune diseases. Therefore, the predisposing gene for
BD may also be involved in other autoimmune diseases in a
similar way. It is necessary to clarify whether the discovered
polymorphisms  of  FCRL3  are  associated  with  other
autoimmune  diseases.  Furthermore,  studies  are  needed  to
investigate whether the observed associations with BD are
also present in other ethnic populations.
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